Taranabant, a novel cannabinoid type 1 receptor inverse agonist

Bradley A Fremming, S. T. Boyd

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Merck & Co Inc is developing the cannabinoid receptor type 1 inverse agonist taranabant for the potential treatment of obesity and nicotine dependence. By October 2006, the drug had entered phase III trials for obesity, and by May 2008, a phase II study of taranabant as an aid to smoking cessation in chronic cigarette smokers had been completed.

Original languageEnglish (US)
Pages (from-to)1116-1129
Number of pages14
JournalCurrent Opinion in Investigational Drugs
Volume9
Issue number10
StatePublished - Oct 7 2008

Fingerprint

Cannabinoid Receptors
Obesity
Tobacco Use Disorder
Smoking Cessation
Tobacco Products
Pharmaceutical Preparations
N-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Taranabant, a novel cannabinoid type 1 receptor inverse agonist. / Fremming, Bradley A; Boyd, S. T.

In: Current Opinion in Investigational Drugs, Vol. 9, No. 10, 07.10.2008, p. 1116-1129.

Research output: Contribution to journalReview article

@article{baa6a60f77d040a4938b8d01ef649ebd,
title = "Taranabant, a novel cannabinoid type 1 receptor inverse agonist",
abstract = "Merck & Co Inc is developing the cannabinoid receptor type 1 inverse agonist taranabant for the potential treatment of obesity and nicotine dependence. By October 2006, the drug had entered phase III trials for obesity, and by May 2008, a phase II study of taranabant as an aid to smoking cessation in chronic cigarette smokers had been completed.",
author = "Fremming, {Bradley A} and Boyd, {S. T.}",
year = "2008",
month = "10",
day = "7",
language = "English (US)",
volume = "9",
pages = "1116--1129",
journal = "Current Opinion in Investigational Drugs",
issn = "1472-4472",
publisher = "Current Drugs Ltd.",
number = "10",

}

TY - JOUR

T1 - Taranabant, a novel cannabinoid type 1 receptor inverse agonist

AU - Fremming, Bradley A

AU - Boyd, S. T.

PY - 2008/10/7

Y1 - 2008/10/7

N2 - Merck & Co Inc is developing the cannabinoid receptor type 1 inverse agonist taranabant for the potential treatment of obesity and nicotine dependence. By October 2006, the drug had entered phase III trials for obesity, and by May 2008, a phase II study of taranabant as an aid to smoking cessation in chronic cigarette smokers had been completed.

AB - Merck & Co Inc is developing the cannabinoid receptor type 1 inverse agonist taranabant for the potential treatment of obesity and nicotine dependence. By October 2006, the drug had entered phase III trials for obesity, and by May 2008, a phase II study of taranabant as an aid to smoking cessation in chronic cigarette smokers had been completed.

UR - http://www.scopus.com/inward/record.url?scp=53049108013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53049108013&partnerID=8YFLogxK

M3 - Review article

C2 - 18821475

AN - SCOPUS:53049108013

VL - 9

SP - 1116

EP - 1129

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1472-4472

IS - 10

ER -